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Objective: Synchronous multiple ground-glass nodules (SM-GGNs) are a distinct entity
of lung cancer which has been emerging increasingly in recent years in China. The
oncogenesis molecular mechanisms of SM-GGNs remain elusive.
Methods: We investigated single nucleotide variations (SNV), insertions and deletions
(INDEL), somatic copy number variations (CNV), and germline mutations of 69 SM-GGN
samples collected from 31 patients, using target sequencing (TRS) and whole exome
sequencing (WES).
Results: In the entire cohort, many known driver mutations were found, including EGFR
(21.7%), BRAF (14.5%), and KRAS (6%). However, only one out of the 31 patients
had the same somatic missense or truncated events within SM-GGNs, indicating the
independent origins for almost all of these SM-GGNs. Many germline mutations with
a low frequency in the Chinese population, and genes harboring both germline and
somatic variations, were discovered in these pre-stage GGNs. These GGNs also bore
large segments of copy number gains and/or losses. The CNV segment number tended
to be positively correlated with the germline mutations (r = 0.57). The CNV sizes were
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correlated with the somatic mutations (r = 0.55). A moderate correlation (r = 0.54) was
also shown between the somatic and germline mutations.
Conclusion: Our data suggests that the precancerous unstable CNVs with potentially
predisposing genetic backgrounds may foster the onset of driver mutations and the
development of independent SM-GGNs during the local stimulation of mutagens.
Keywords: lung cancer, ground-glass nodule, whole-exome sequencing, copy number variation, driver mutations
INTRODUCTION
The widespread use of advanced chest computed tomography
(CT) for lung cancer screening has facilitated the detection of
ground-glass nodules (GGNs) (1–3). Recent data indicates
that up to 20% of GGN patients (3% of the screening
population) are diagnosed with synchronous multiple
ground-glass nodules (SM-GGNs) (4). GGNs are like
atypical adenomatous hyperplasia (AAH), adenocarcinoma
in situ (AIS), minimally invasive adenocarcinoma (MIA), or
invasive adenocarcinoma (AD) (5). To date, neither auxiliary
tests that can assist in the differential diagnosis (6) nor
recommended strategies for the identification and treatment
of GGNs exist in clinical practice guidelines for lung cancer.
In fact, a major clinical challenge is to distinguish between
independent synchronous multiple primary lung cancer
(SMPLC) and intrapulmonary metastasis, which makes a
treatment decision difficult. Thus, molecular characterization
of GGNs may provide insight into the genetic drivers of
synchronous multiple tumors and identify inter-tumor
heterogeneity (7–9).
Although SM-GGNs appear within the same environmental
and genetic background as GGNs, SM-GGNs may comprise
of a complex combination of different gene alterations and
distinct morphologic characteristics (10). Currently available
genetic evidence for lung cancer metastasis suggests that the
time between the development of two tumors is important
in distinguishing SMPLC from metastasis (6). Synchronous
metastases have largely preserved genetic patterns identical to
those of the primary lung cancer (11, 12). Next-generation
sequencing (NGS) has revealed that solid tumors, including lung
cancer, harbor thousands of single-nucleotide variations (SNVs)
and ten to hundreds of somatic chromosomal rearrangements
(SVs) (13, 14). Both alterations have been used to analyze the
lineage relationships between tumors from the same individual.
However, the results of matched analyses of the concordance
of cancer molecular characteristics and genetic patterns in
SMPLC, have been discrepant and inconclusive (10, 15, 16).
A cluster analysis has been used to identify copy number
variation (CNV) patterns (17, 18). According to the results
of the TRACERx group (19), whole-genome duplication and
CNV are early events in non-small-cell lung cancer (NSCLC)
evolution; higher copy-number variation heterogeneity has been
found to be a risk factor for recurrence or death (hazard
ratio, 4.9; P = 4.4× 10−4).
In this study, we conducted deep genomic sequencing to
explore the genomics of SM-GGN. Our data showed that
TABLE 1 | Patients’ clinical information.
Target/whole exom sequence Total
Clinical AAH AIS MIA AD GGNs
Sample# 25/0 13/9 5/5 8/4 69
Sample type FFPE 25/0 13/0 5/0 8/0 51
Frozen 0/0 0/9 0/5 0/4 18
Control tissue lymph node 25/0 13/0 5/0 8/0 51
adjacent lung 0/0 0/9 0/5 0/4 18
Stage T1N0M0 25/0 13/9 5/5 8/4 69
Size(cm) <0.5 7/0 0/3 0/0 0/0 10
0.5–1 18/0 13/6 5/5 1/4 52
1–2.5 0/0 0/0 0/0 7/0 7
Age (years) <60 12/0 6/3 3/3 4/0 31
≥60 13/0 7/6 2/2 4/4 38
Gender Male 7/0 3/2 0/1 4/0 17
Female 18/0 10/7 5/4 4/4 52
Smoking Yes 0/0 0/2 0/1 0/0 3
No 25/0 13/7 5/4 8/4 66
Follow-up (year) <2 0/0 0/0 0/0 0/0 0
>2 25/0 13/9 5/5 8/4 69
Disease-free Yes 25/0 13/9 5/5 8/4 69
Atypical adenomatous hyperplasia (AAH), Adenocarcinoma in situ (AIS), Minimally
invasive adenocarcinoma (MIA), Invasive adenocarcinoma (AD), and Ground-glass
nodules (GGNs).
the similar CNV instability and a predisposition genetic
background may foster the onset of driver mutations
for the pre-stage lung adenocarcinomas, presenting
as SM-GGN.
RESULTS
Patient Clinical Information and
Sequencing Statistics
Detailed clinical features of the 51 SM-GGN samples collected
from 25 patients and 18 triple SM-GGNs from six patients are
summarized in Table 1. Most patients were females (52/69).
Only three patients were smokers. All were disease-free for
more than 2 years after surgery resection. 50–78% of tumor
cells were ensured in all samples (Tables S1, S2). Two hundred
twenty gene panel (Table S3) was used for TRS. The sequencing
depth and coverage for both TRS and WES are summarized
in Table S4.
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Pre-stage Lung Adenocarcinomas Have
Known Driver Mutations
Our analytical flow is depicted in Figure 1. Among the
panel of 220 cancer genes that were analyzed by targeted
sequencing, we identified 3,356 somatic SNVs from the
51 SM-GGN samples, with 3,049 SNVs harboring unique
mutations, across exonic (139) and intronic or intergenic regions
(2,917; Figure S1a). There were 90 unique nonsynonymous
mutations within 61 genes. In addition, among a total of
68 somatic INDELS, 15 INDELs were found within 10
genes. There was a total of 97 unique non-synonymous
somatic variations (in 65 genes) after the SNVs and INDELs
were combined (Figure 1). Many of the genetic alterations
are known driver mutations, including BRAF (18%), EGFR
(12%), KRAS (8%), MUC4 (8%), POLE (4%), and MET
(2%) (Figure 2A).
When examining the driver mutations using WES, 7,640
somatic SNVs were discovered with 6,736 unique mutations
from 18 GGNs from six patients, with 721 exonic and 29 in
splicing sites (Figure S1b). There were 530 non-synonymous
mutations (502 unique) within 477 genes, and 80 somatic
INDELS had 13 non-synonymous INDELS within 12 genes.
Among a total of 515 unique non-synonymous somatic
SNV/INDELs, nine out of 18 GGNs (50%) had an EGFR
mutation (Figure 2B).
Common Driver Genes With Different
Mutations Among SM-GGNs
SM-GGNs shared very few or no common missense or truncated
driver-mutated driver genes (Figure 2A). Within the same
genes, different mutation events were detected (Table S5). For
instance, the paired M10AAH and M10MIA shared the same
driver gene variant BRAF; however, they were different types
of events. Five different BRAF mutation events occurred in
exon 15 (BRAFK601E, BRAFL597R, BRAFD594N, BRAFN581S,
BRAF1T599), 3 on exon 11 (BRAFG469A, BRAFG469V),
1 in exon 12 (BRAF1486_491), M8AAH and M8AD had
different missense mutations of the same gene, MUC4,
which were not at the same loci of the gene (MUC4P3826L,
MUC4D3797N, MUC4A3321V, MUC4D2261N). In WES, 50% (9/18)
of the GGN samples had EGFR SNV/INDELs (Figure 2B).
Among all 69 GGNs from 31 patients, only one patient
(M2) had the same EGFR mutation event in all SM-GGNs
(Tables S6, S7).
The common silent somatic mutations were very low, with 1–
16 common somatic SNV/INDELs among 22 patients and none
common in 3 patients in TRS data. There are 7, 9, 10, 7, 13, and
10 common silent SNV/INDELs detected among the triple GGNs
of the same M1 to M6 patients, respectively, in WES data.
Pre-stage Nodules Have Fewer Driver
Mutations Than Advanced Lesions
In TRS, the average somatic SNV/INDELs were 69.4, 53.3, 64,
and 84.5 for AAH, AIS, MIA and AD, respectively. However,
there were no significant differences between all groups. The
average non-synonymous SNV/INDELs were 1.6, 1.92, 1.2, 4.25
for AAH, AIS, MIA, and AD, respectively. However, there was
a significant difference between AAH vs. AD (P = 0.023) and
combined, AAH, AIS, and MIA vs. AD (P = 0.025) in missense
somatic variations.
In WES, the average somatic SNV/INDELs were 417.3, 412.5,
500 for AIS, MIA, and AD, respectively, and there were no
significant differences among these types. The average of the non-
synonymous somatic SNV/INDELs of 41 AD was 1.45-fold of
AIS (28; P = 0.9) and MIA (28.5; P = 0.5), although it was not
statistically significant.
We compiled the profiles of the 5′ and 3′ conjugated bases
of all somatic SNVs of each GGN sample and expected that
some mutation signatures may represent the mutagenesis (20)
specific to all GGNs or some types of GGNs. TRS data showed
predominant somatic signature 1 and 16 in all four types of
GGNs. In addition, AIS bore signature 29, and AD had signature
26 (Figure 3). TheWES data showed a different signature profile.
Signature 3 was predominant, following signature 1. All three
types of GGNs from 18 GGN samples had a similar signature
profile: 1, 3, 6.
There Were High Burden Germline
Mutations in GGN Patients
In TRS, 994,089 germline SNP/INDELs were discovered,
with an average of 39,763 from each patient. Of the 1,438
variants, 280 had ≤ 0.01 MAF in a Chinese population
derived from 2,220 whole-exome sequencing and 568 whole-
genome sequencing data. Interestingly, some important cancer
gene variants were found in patients (3 TP53, 3 BRCA2, 3
FGFR3) (Table S8).
In WES, a total of 1,636,397 SNP/INDELs were discovered
in five patients, consisting of approximately 345,000 each.
The 24,085 genes bore germline variants. Further filtering
with 0.01 MAF of Chinese populations revealed 2,323
mutations in 1,990 genes. In these 6 patients, 100% (6/6)
had a TRIP10 missense mutation, and 83% (5/6) had
a non-frameshift insertion in MICALCL and PPP2R2B
(Table S9). We also found the cancer gene BRCA1 variant in
one patient.
Predisposition Gene Mutations in
GGN Patients
From 25 germline TRS data, we discovered a total of 1,744
variants (448 unique variants) in 39 known predisposition
genes of genetic diseases from Human Gene Mutation Database
(HGMD) and Online Mendelian Inheritance in Man (OMIM)
databases (Table S10, Figure S2).
We further examined only the 280 missense/truncated
and infrequently observed Chinese MAF mutations using
TRS, and we found several predisposition gene mutations,
including the previously reported lung cancer susceptible
gene CHRNA3 and several cancer gene germline mutations
including BRAC1, BRAC2, EGFR, and TP53 (Table S8). From
the 2,323 missense/truncated with low-frequency Chinese MAF
from WES, TRIP10, MICALCL, and PPP2R2B had the highest
frequency among the 6 WES patients.
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FIGURE 1 | Overview of genomic variant analyses of 69 GGN cases. The Targeted sequencing data and whole-exome sequencing data were analyzed separately for
the variants. SNV, single nucleotide variations; INDEL, insertions and deletions; CNV, copy number variations; SM-GGN, Synchronous multiple ground-glass nodules.
Genes Burden With Both Germline and
Somatic Mutations
We next examined the top genes that had both nonsynonymous
somatic mutations and germline mutations in our cohorts
(Figure 4). Among the five somatic missense/truncated variants
and 6 germline missense/truncated low MAF variants in
MUC4, one variant was predicted to be deleterious by
PROVEAN(21), and three were predicted to be damaging
by SIFT(22) (Table S11). Among the 12 variants of gene
FLG, two missense SNPs were predicted to be damaging
by SIFT. Using muPIT Interactive (23) and RCSB PCB
(24), we confirmed the harmful effects on protein structure
predicted by SIFT and PROVEAN. Each SNP resulted in
a dramatic alteration of protein structure, and we analyzed
the impact of this functional perturbation on other genes
and pathways.
FLG interacts with MCL1, USP1, C21orf59, MAK, and
KIR3DS1 and mucin interacts with ERBB3, SNAI1, TWIST1,
TWIST2, and CDH2, all of which, IPA predicted to be associated
with cancer (Figure S3).
The Pre-stage GGN Showed Chromosome
Instability by CNV
We performed a clustering analysis of CNV using all paired
SM-GGNs (Figure 5A). The paired GGNs were not clustered
except M18, M5, and M1 patients. Interestingly, the similar
types of GGNs tend to be clustered. For example, the cluster
C2 had 5 AD out of seven members and cluster C5 had 8
AAH out of 11 members. However, this observation appears
differently in WES data. As shown in Figure 5B, all triple SM-
GGNs were clustered within the same patients by CNV. This
result suggests that CNVs derived from a region beyond the
cancer gene panel may represent the overall of the same patient.
Using WES, 30 regions of gain and 5.5 regions of loss, 15Mb
and 6Mb, respectively, were found in each GGN. Interestingly,
the CNV gain size or total CNV size showed a moderate positive
correlation (r > 0.5) with the somatic mutations, while the CNV
gain or loss segment number or total number correlated with
the germline mutations (r > 0.5) (Figures 5C,D and Table S12).
Our data uncovered a correlation between germline mutation
and somatic mutations in GGN patients, though such CNV
correlations were not found in the CNV data from the TR
samples (Table S13).
Evaluation of Truncal and Branched
Driver Mutations
Since there were very few non-silent variants for each GGN,
we included all somatic variants (SNV/INDELs) to construct
phylogenetic trees using the parsimony method (25) with
branch lengths reflecting the number of mutations. We
labeled the key driver mutation during the acquisition process.
All the potential predisposition gene mutations shown in
Figure 6 have been previously reported to associate with
lung or other cancer risks, and all had ≤ 0.01 MAF in
Chinese populations. As shown in Figures 6A–F, the SM-
GGNs of the six patients did not originate from the same
ancestor clones.
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FIGURE 2 | Somatic variant detections. Somatic SNVs were detected by MuTect and INDELs were identified by StrelKa. Variants in genes with missense/truncated or
in splicing sites (patho-variants) were identified, ranked, and displayed by paired samples. (A) Patho-variants detected from Targeted sequencing. (B) Patho-variants
detected from whole-exome sequencing.
DISCUSSION
In this study, we found that the six triple SM-GGNs and 25
double SM-GGNs were from independent origins, because the
SM-GGNs of the same patient shared none or very few common
driver mutation events or somatic mutations. This confirmed
a previous study that used data from two patients (26). If the
metastasis model can help perceive how some types of SM-GGNs
occurred by metastasis spread (27), understanding how multiple
GGNs occurred independently is elusive, which motivated us to
deeply explore our data. We proposed several possible models
for SM-GGN development (Figure 7). We found our data
represented an inherent sporadic SM-GGNs (ISG) model. ISG
typically does not exhibit identical driver mutations; however,
germline predisposing mutations and similar chromosome
alterations bring about many GGNs simultaneously (Figure 6).
Izumchenko et al. (15) applied targeted sequencing on 25
distinct AAHs that were incidentally discovered in lung resection
specimens from six patients with invasive adenocarcinoma.
They found that one of six primary tumors harbored BRAF
mutation and three of four patients with mutated BRAF in AAHs
carried wild-type BRAF in paired invasive adenocarcinoma.
EGFR, TP53, and KRAS mutations were found in several
AAHs and matched primary tumors of two patients. This is
probably the earliest report that some SM-GGNs originated
from metastasis (27) (Figure 7). SM-GGNs may also be derived
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FIGURE 3 | Somatic mutational signatures deconstructed from GGN samples. (A) The average somatic mutation spectra of the AAH, AIS, MIA, and AD groups were
obtained from variants (SNV/INDELs) of 25 AAH, 13 AIS, 5 MIA, and 8 AD TRS samples (left). The somatic signatures of AIS (mean of 9 AIS), MIA (mean of 5), and AD
(mean of 4) detected from 18 WES data are displayed (right). (B) The bar chart represents the proportions of the signatures in each group.
from multiple local primary tumors. In agreement with a
recent study demonstrating independent clonal origins of SM-
GGNs (26), we did not find significant overlapping variant
sets between any tumor pair in each of these 31 patients.
This observation suggested that multiple pulmonary nodules
within one subject probably arose autonomously from different
progenitor cells. These SM-GGNs shared an identical germline
genetic background and environmental exposure in individual
patients. We hypothesize that there are three phenotypes with
sporadic ancestor origins (Figure 7).
Kobayashi et al. (28) found EGFR mutations in 64% of 104
GGNs, KRAS in 4%, ALK in 3%, and HER2 in 4%. Our data
also supports the ISG model and our somatic mutation findings
are similar to those in previous reports, where BRAF, EGFR, and
KRAS were the top driver mutation GGNs. In our study, we did
not find somatic TP53mutations in both TRS and WES cohorts.
This result is consistent with previous reports where the TP53
mutation was not found (27) or the TP53 mutation was not
among the top driver mutations in GGNs (15, 26). This indicates
that GGN is distinct from typical invasive lung cancer in which
TP53 mutations were the most frequent among all other driver
genes (29).
The inherent sporadic SM-GGNs typically do not exhibit
identical driver mutations; however, germline predisposing
mutations and similar chromosome alterations bring about
many GGNs simultaneously. Therefore, although occurring
independently, they are linked by the genetic background and
similar CNVs. The two cohorts in our study were this type of
SM-GGNs. No identical drive mutations were found, but these
patients had a large number of germline mutations, potential
predisposition mutations, and large chromosome gain and loss
segments. Different known driver mutations were acquired in the
evolution branches.
In addition, our study showed that independent clonal
SM-GGNs (ICG) do not have identical driver mutations nor
typical predisposition mutations. These SM-GGNs do not
have any genetic link; therefore, they occur randomly and
occasionally. We hypothesize that ICG may prone to the
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FIGURE 4 | Lolliplots showing the distribution of germline and somatic variants in the top two genes, FLG (A,B) and MUC4 (C,D). For those germline variants that
had >0.01 Chinese MAF, only those variants that were predicted to be deleterious by PROVEAN or damaging by SIFT are displayed (red star). The X-axis represents
the exon and chromosome location. The Y-axis represents the occurrence of variants in GGNs (somatic) or patients (germline). The distribution of variants in AAH
GGNs (upper panel) (A,C) was compared with that in other GGNs (bottom panel) (B,D).
Frontiers in Oncology | www.frontiersin.org 7 April 2019 | Volume 9 | Article 288
Ren et al. Genomic Variations of Lung SM-GGNs
FIGURE 5 | Unsupervised hierarchical clustering of copy number variations among GGNs and correlations between CNV and mutations. (A) CNVs of 51 SM-GGNs
from TRS data were clustered by Pearson correlation. (B) Eighteen triple GGNs from the WES data also showed correlation patterns within each patient by clustering.
Pearson correlation analysis was performed. (C) Pearson correlation between total CNV segment number and germline nonsynonymous mutations of WES data. (D)
Correlation between total CNV size and all somatic mutations of WES data. (E) Correlation between all germline and somatic mutations of WES data.
deficient local immune microenvironment or presumably to
the biochemical substances released from the primary tumor
lesion (30).
It is believed that many types of mutagens can increases
the frequency of mutations above the natural background level,
resulting in driver gene mutations at the pre-stage. Additional
molecular alterations later progress the cancer development (31,
32). As the germline mutations and copy number alterations
occurred in the pre-stage of GGNs, we suggest these genomic
factors may foster the mutation acquisition during the local
stimulation of mutagens such as air pollutants. Interestingly, our
data showed a moderate correlation between global germline and
somatic mutations (Figure 5E). High burden germlinemutations
may predispose individuals to driver mutation acquisition, and
the genes bearing the highest mutation frequency could play
potential roles as cancer drivers.
Somatic mutations are an accumulation process. Signature 1
has been found in all cancer types and in most cancer samples
(20). This finding suggests that a similar mutational process
operated to promote tumorigenesis in SM-GGNs. Signature 3
is strongly associated with germline and somatic BRCA1 and
BRCA2 mutations in breast, pancreatic, and ovarian cancers,
which was previously reported in GGNs (20).
CNV reflects the instability of chromosomes. Our study
showed large segments of amplification gain/loss in GGNs.
The gene gains or losses caused by CNV can result in
tumorigenesis. The abnormal amplification of chromosome
segments may increase the error rate during DNA replication
process. Interestingly, our data showed the CNV segment
number positively was correlated with the germline mutations
and the CNV size was correlated with the somatic mutations.
Though it is not clear why the CNV showed the different
correlation favors, our data demonstrated a relation between
mutations and CNV in SM-GGNs. We also found that many
patients had similar overall profiles of somatic CNV among SM-
GGNs. The similar overall CNVs provide an atmosphere for
developing synchronous multiple GGNs in the same patient. The
TRS analysis showed more CNV segments and sizes, most likely
due to overestimation by the techniques and the control samples.
This is challenging as the control-FREEC software inferring
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FIGURE 6 | Phylogenic tree view of the triple GGN evolution structure. All somatic variants (SNV/INDELs) detected from whole-exome sequencing were compared
among the three GGNs of the same patients. The key potential driver mutations acquired at a particular point are indicated. The trees showed genetic similarity (trunk)
and dissimilarity (branch) of the SM-GGNs. Six patients of WES cohort: (A) patient M1; (B) M2; (C) M3; (D) M4; (E) M5; (F) M6.
FIGURE 7 | Proposed SM-GGN origination models. Five models plus an unknown process were hypothesized. These different originations could occur in different
cases, or even mixed in one patient. There are evidence supporting the lymph metastasis SM-GGNs, aero metastasis SM-GGNs, Convergent SM-GGNs (CVG), and
the inherent sporadic SM-GGNs (ISG). The independent clonal SM-GGNs (ICG) we hypothesize is prone to the deficient local immune microenvironment or
presumably to the biochemical substances released from the primary tumor lesion.
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whole genome-wide CNVs from the limited targeted regions can
affect CNV calls by off-target reads.
We acknowledge that, despite using a large size of 69 SM-GGN
lesions, the 31 patients in the study was not enough to detect less-
common genomic alterations, though sample sizes of two (27), 4
(26), six (15), and 9 (33) patients have been previously reported
in similar GGN studies. Expanding our knowledge in this area
will require a major international collaboration. Likewise, we
acknowledge that although our predictive findings demonstrate
the power of molecular data in guiding management decisions,
a prospective clinical trial using predictors derived from our
data will be required before clinical use. Also, various of analysis
including RNA-seq, epigenetic seq will be required for deeper
research on SM-GGNs.
In summary, we have comprehensively explored the genomic
variations of 69 SM-GGN samples of 31 patients. Our data
demonstrated that SM-GGNs shared similar overall patterns
of large segments of copy number gains and/or losses and
potential predisposition gene mutations in the independent
origin of SM-GGNs. The CNVs were correlated with germline
and somatic mutations, and the global germline mutations were
correlated with somatic mutations. These results might suggest
that the unstable CNV with potential predisposition genetic
background probably can foster the onset of driver mutations
for the development of independent SM-GGNs (Figure 6) during
local stimulation of mutagens such as air pollutants. The
candidate genes, BRIP1 with high germline mutations, MUC4,
and FLG harboring both germline and somatic mutations,
may provide an avenue to further study how driver mutations
were predisposed in the development of SM-GGNs. Since the
molecular abnormities found in previous studies were still not
conclusive in relation to the tumorigenesis among the SM-GGN
or GGN tumors, our findings here provide insight into the
biology of SM-GGNs.
MATERIALS AND METHODS
Patients and Tissue Samples
Tumor samples were obtained from patients who underwent
surgical resection at the Shanghai Pulmonary Hospital between
2014 and 2015. Two cohort samples were collected, one for TRS
(51 GGNs) and the other for WES (18 triple GGNs). All case
included in the study met the proper indication, including (a)
all treatment decisions were made by a multidisciplinary team.
(b) all cases with a dominant nodule, which was suspected as an
invasive lung cancer. (c) ground-glass nodules were suspected as
invasive lung cancer in the following circumstances: (1) nonsolid
nodules measuring > 10mm; (2) Nonsolid nodules that grow or
develop a solid component in the follow-up. Two pathologists
reviewed all samples to confirm the histology and assess the
tumor content according to the 2011 International Association
for the Study of Lung Cancer (IASLC). Tumor cell proportion
of all samples, GGN site, and sizes were summarized (Tables S1,
S2). The cells were counted under 100X microscopic vision
using the average of the sum counts in five randomly selected
fields of each lesion. Per previously reviewed studies, we used
either the matched normal mediastinum lymph node tissue (15)
or normal lung tissues (26, 29–34) for germline variant calling
and as the control for somatic variant calling. The institutional
Ethics Committee of the Shanghai Pulmonary Hospital approved
the study. Written consent was obtained from the patients in
this study.
Targeted Sequencing (TRS)
DNA was extracted using a TIANamp FFPE DNA Kit
(TIANGEN) and quantified with the Nanodrop system (Thermo
Scientific). Matched normal lymph node tissue was used in each
case as a control. Targeted region sequencing was performed
at Novogene, Inc. A paired-end DNA library was prepared
according to the manufacturer’s instructions (Agilent); 1 µg
of tumor DNA was sheared into 180–280-bp fragments using
a Covaris S220 sonicator. The ends of the gDNA fragments
were repaired, and the 3′ ends were adenylated. Both ends of
the gDNA fragments were ligated at the 3′ ends with paired-
end adaptors (Illumina USA) with single “T” base overhang
and purified using AMPure SPRI beads from Agencourt.
The adaptor-modified gDNA fragments were enriched via 6
cycles of PCR using SureSelect Primer and SureSelect ILM
Indexing Pre-Capture PCR Reverse Primer. The concentration
and size distribution of the libraries were determined on an
Agilent Bioanalyzer DNA 1000 chip.Whole-target regain capture
was performed using Agilent’s Sure Select XT Custom. The
captured DNA library was sequenced on an Illumina Hiseq 4000
according to the manufacturer’s instructions for paired-end 150-
bp reads. The libraries were loaded onto paired-end flow cells
at concentrations of 14–15 pM to generate cluster densities of
800,000–900,000/mm2 using an Illumina cBot and HiSeq paired-
end cluster kit.
Whole-Exome Sequencing (WES)
DNA was extracted using a QIAamp DNA Mini Kit (QIAGEN,
Shanghai, China) and quantified with the Nanodrop system
(Thermo Scientific, Shanghai, China). Matched normal
lung tissue was used in each case as a control. Whole-
exome sequencing (WES) of the samples was performed at
Novogene, Inc. (Beijing, China). Sequencing libraries were
generated using the Agilent SureSelect Human All Exon
kit (Agilent Technologies, CA, USA). Fragmentation was
carried out using the hydrodynamic shearing system (Covaris,
Massachusetts, USA) to generate 180–280-bp fragments. The
remaining overhangs were converted into blunt ends using
exonuclease/polymerase activities. After adenylation of the 3′
ends of DNA fragments, adapter oligonucleotides were ligated.
The captured libraries were enriched in a PCR reaction to add
index tags to prepare for sequencing. Products were purified
using the AMPure XP system (Beckman Coulter, Beverly, USA)
and quantified using the Agilent high sensitivity DNA assay on
the Agilent Bioanalyzer 2100 system. Clustering of the index-
coded samples was performed on a cBot Cluster Generation
System using the Hiseq PE Cluster Kit (Illumina) according to
the manufacturer’s instructions. After cluster generation, the
DNA libraries were sequenced on the Illumina Hiseq platform,
and 150-bp paired-end reads were generated.
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Sequence Quality Check and Mapping
We first checked the quality of the base call of the Hiseq sequence
reads, and we ensured an average score of Q30 with more than
80% and an error rate < 0.1%. In addition to removing the
adaptor sequence bases, we also removed those read pairs that
had more than 10% uncertain bases (N) among a whole read,
and those that had a length of more 50% of a read with a
low-quality score (Q5). The Burrows-Wheeler Aligner (BWA)
software (35) (Version 1) was used to map the paired-end clean
reads to the reference genome (UCSC hg19). BWA chooses the
best math mapping location if a read can be mapped on multiple
locations. We then checked the read coverage and depth of each
sample. We examined the properly paired mapped rate, coverage
of the targeted regions, and fraction of targeted regions with
different depths.
SNV/INDEL Call
Samtools mpileup (36) was used to perform variant calling and
to identify SNVs and indels in tumor and normal samples.
We used a minimum number of two gapped reads for indel
candidates and 0.002 as the minimum fraction of gapped reads.
We skipped the alignments with mapQ smaller than 1. The
final calls were filtered with a base call Q score >20, read
depth >4, and mapping quality > 30. These SNV/INDELs
were used for further germline variation analysis. The variant
allele frequencies (VAF) of the germline SNPs were examined
(Table S14). The somatic SNVs were detected by muTect
(37), and the somatic INDEL were detected by Strelka (38).
We applied the Refseq and Gencode of HG19 to annotate
these variations, including chromosome loci, gene structure
(UTR, intronic, exonic, intergenic), function affects (missense,
splicing, synonymous), and types (mRNA, non-coding RNA,
small RNA).
CNV Analysis
The targeted sequencing data can be used to infer CNV (39),
although it only covers a small portion of the whole genome.
The off-target sequences have also been used to infer CNV.
We used the Control-FREEC software for CNV detection
(40). First, Control-FREEC obtains input aligned reads and
counts reads (RC) in non-overlapping windows. The second
step is profile normalization by fitting to the control RC. The
observed RC in ploidy P-copy regions (i.e., regions with a
copy number equal to P) can be modeled as a polynomial
of the control RC, and the observed RC in a region with
an altered copy number is linearly proportional to the RC
in P-copy regions. The third step is segmentation of the
normalized CNV profile using a LASSO-based algorithm by
Levy-Leduc and Harchaoui (41). The last step involves analysis
of the segmented profiles, which includes the identification of
regions of genomic gains and losses and the prediction of copy
number changes in these regions. The heat-maps of somatic
CNVs were analyzed using Complex Heatmaps [https://github.
com/jokergoo/ComplexHeatmap], according to the study by Ni
et al. (18).
Mutation Signature Analysis
We deciphered the somatic mutation signatures in GGN
types using the R package “deconstructSigs” (42). Briefly, for
each tumor sample, we extracted the 5′ and 3′ sequence
context of each mutation from the hg19 reference genome,
and the SNVs were categorized into C>A, C>G, C>T, T>A,
T>C, and T>G bins according to the type of substitution
and then subcategorized into 96 sub-bins according to the
nucleotides preceding (5′) and succeeding (3′) the mutated
base. We then groped the samples into four classes, AAH,
AIS, MIA, and AD, and calculated the mean frequency of
each of the 96 mutations. We downloaded the 30 known
mutation signatures from the COSMIC website (43). To
enable comparisons with the known signatures based on
the Wellcome Trust Sanger Institute Mutational Signature
Framework, the “deconstructSigs” (42) allowed us to compare
our mutation profiles against the COSMIC signatures and
statistically quantify the contribution of each signature to each
group of GGN tumors.
Mutation Integrative Analysis
SNP data were divided based on whether an SNP was from a
germline or somatic samples. To filter and maintain significant
SNPs for the germline, VAFs for each of the SNPs were
determined from a private Chinese collaborator and the 1000
Genomes Project (44). Only SNPs with a VAF with no entry
or ≤ 0.01 were retained. Somatic SNPs did not need to be
filtered by VAF. The SNPs were pooled into AAH and the
other GGN types separately. Reference SNP IDs were determined
using the UCSC Genome Browser (version 138) (45). In
addition, before filtering by VAF, SNP data were plotted for
comparison. The SNPs of each gene were also separated into
AAH and others.
All remaining SNPs were analyzed using SIFT and PROVEAN
to predict whether they were damaging or harmless. SIFT
first obtains sequences related to the query sequence and
chooses closely related sequences that have a similar structure
and function. It calculates probabilities of amino acids using
Dirichlet mixtures. The cutoff for being deleterious is a score
of 0.05 (determined from comparison to experimental data)
(22). PROVEAN clusters BLAST hits and the clusters most
related to the query are used to generate a PROVEAN
score prediction. If the score is less than −2.5 (default score
threshold), then the mutations are classified as deleterious
(21). Their effects on other genes and pathways were analyzed
using Ingenuity Pathway Analysis (IPA) (46). We ranked
the germline mutations, and selected the genes that had
the highest number of germline mutations with at least one
somatic mutation.
Construction of Trunks and Branches of
Driver Mutations
All somatic mutations, including silent mutations, were
considered to evaluate the phylogenetic trees. Trees were
constructed using binary presence/absence matrices built from
the regional distribution of variants within the tumor. The
parsimony distance method was applied to generate rooted
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trees (25). Branch lengths were determined using the number
of mutations.
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